The company expects to launch Altrazeal in Austria in October 2012.
Melmed Holdings chairman Helmut Kerschbaumer said the clinical and economic advantages that have been demonstrated are significant benefits that make Altrazeal a unique product in the wound care market.
"Also, its ability to inhibit bacterial growth over an extended period when used with different antiseptics is considered a major marketing opportunity," Kerschbaumer added.
"The properties of Altrazeal including extended wear time, reduced wound care provider treatment time and clinical outcomes make it an ideal product for the European market."
Altrazeal is a scientifically engineered material that incorporates the features and benefits of the desired ideal wound dressing, according to the company.
Altrazeal demonstrated potential clinical and economic advantages in a number of chronic and acute wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcer, and geriatric wounds.
ULURU president and CEO Kerry Gray said, "The necessary pre-marketing activities to ensure a successful launch are being conducted which gives us great confidence that Altrazeal will be a significant competitor in the advanced wound care market."